**Core tip:** We investigated whether the location of the inserted pancreatic stent rather than pancreatic stent length influenced the frequency of post-endoscopic retrograde cholangiopancreatography (ERCP) hyperamylasemia and post-ERCP pancreatitis (PEP). Pancreatic amylase isoenzyme levels after ERCP were significantly higher in the head group than in the body/tail group. PEP did not occur in the body/tail group. Stent insertion into the pancreatic head was an independent risk factor for hyperamylasemia after ERCP, while stent insertion up to the pancreatic body or tail reduced the risk of post-ERCP hyperamylasemia and may reduce the risk of PEP.

INTRODUCTION
============

Endoscopic retrograde cholangiopancreatography (ERCP) plays a significant role in endoscopic investigation and treatment for cholangiopancreatic diseases. However, a serious adverse effect of ERCP is pancreatitis. Previous studies have found that post-ERCP pancreatitis (PEP) occurs in 0.4%-5.6% of cases\[[@B1]-[@B8]\], and that mortality from PEP occurs in 0-0.1% of cases\[[@B4],[@B6]-[@B8]\]. Pancreatic stents have been shown to be useful for preventing PEP\[[@B9]-[@B22]\]. The adaptation of pancreatic stent insertion to prevent PEP has been reported in the contexts of sphincter of Oddi dysfunction, a history of pancreatitis or PEP, difficulty with biliary duct cannulation, pancreatic duct cannulation, and others\[[@B23]\]. Despite pancreatic ductal stent insertion, PEP was reported to occur in 1.7%-20% of these cases\[[@B12]-[@B18]\]. The pancreatic stent that should be used is unclear (size, with flap or without flap, insertion location, *etc*.). One study found that a 5-Fr pancreatic stent was easier to insert than a 3-Fr pancreatic stent\[[@B24]\], and another reported that a 5-Fr pancreatic stent was similarly effective as a 4-Fr pancreatic stent in preventing PEP\[[@B25]\]. An additional report stated that insertion of a pancreatic stent with a diameter \> 5 Fr was effective in preventing PEP\[[@B22]\]. The incidence of PEP, however, was not reduced in most reports. Meanwhile, two reports have discussed the length of the pancreatic stents. Fujisawa et al\[[@B26]\] compared pancreatic stent lengths (unflapped straight stent, 5 Fr at 3 cm *vs* 5 Fr at 5 cm) and reported that the PEP rate and the median time until stent migration were lower in the 3-cm group than in the 5-cm group. However, pancreatic sizes varied, and 3-cm or 5-cm pancreatic stents were primarily inserted at the pancreatic head. Olsson et al\[[@B22]\] reported that a pancreatic stent with a length \> 5 cm and a diameter \> 5 Fr is most effective in preventing PEP. The independent efficacy of a longer pancreatic stent to prevent PEP remains unknown.

Therefore, we investigated whether the location of an inserted pancreatic stent rather than the pancreatic stent length influenced the frequency of post-ERCP hyperamylasemia and PEP.

MATERIALS AND METHODS
=====================

Study design
------------

In this retrospective study, we compared the efficacy of pancreatic ductal stent insertion between patients with a stent inserted into the pancreatic head and patients with a stent inserted up to the pancreatic body or tail. This study was approved by the Institutional Review Board of Fukushima Medical University.

Patients
--------

In all, 296 patients underwent their first ERCP procedure and had a pancreatic stent inserted at our hospital between January 2007 and November 2017 (Figure [1](#F1){ref-type="fig"}). Among these patients, 147 underwent ERCP primarily for biliary investigation and had a stent inserted to prevent PEP and were included in this study. We divided these patients into two groups: 131 patients with a stent inserted into the pancreatic head (head group) and 16 patients with a stent inserted up to the pancreatic body or tail (body/tail group). The location of the inserted pancreatic stent was determined by X-ray during ERCP (Figure [2](#F2){ref-type="fig"}).

![Subjects in this study. A total of 296 patients underwent their first ERCP procedure and had a pancreatic stent inserted at our hospital between January 2007 and November 2017. Among these patients, 147 who received ERCP primarily for biliary investigation and had a stent inserted to prevent post-ERCP pancreatitis were included in this study. We divided these patients into two groups: 131 patients with a stent inserted into the pancreatic head (head group) and 16 patients with a stent inserted up to the pancreatic body or tail (body/tail group). ERCP: Endoscopic retrograde cholangiopancreatography.](WJG-24-2392-g001){#F1}

![Inserted pancreatic stent. A: A pancreatic stent (Geenen 5 Fr, 5 cm) was inserted into the pancreatic head; B: A pancreatic stent (Geenen 5 Fr, 7 cm) passed the angle between the pancreatic head and body and was inserted up to the pancreatic body or tail.](WJG-24-2392-g002){#F2}

In total, 149 patients were excluded from this study because 102 patients underwent ERCP primarily to investigate the pancreatic duct, 14 patients had a Vater's papilla tumor or pancreatic cancer invasion to Vater's papilla, 13 patients contracted acute pancreatitis before ERCP, eight patients had hyperamylasemia before ERCP, six patients had part of the stomach resected, four patients did not have amylase isozyme measurements after ERCP hyperamylasemia, one patient did not have images from the ERCP, and one patient had malfusion of the pancreaticobiliary ducts.

ERCP procedures
---------------

All the patients had an endoscope inserted after they were sufficiently sedated with midazolam. After the endoscope reached the descending part of the duodenum, biliary cannulation was initiated. When a guidewire was passed into the pancreatic duct or contrast media was injected, the guidewire was placed in the main pancreatic duct (MPD) as deep as possible by pancreatography. We injected contrast media as sparingly as possible to confirm MPD placement. After biliary cannulation was achieved, a pancreatic stent was inserted. If biliary cannulation was difficult, we inserted a pancreatic stent and performed a precut of Vater's papilla. The lengths of the pancreatic stents were determined randomly by the endoscopists. If the patient was diagnosed with PEP or elevated serum pancreatic amylase isoenzyme (p-AMY) (≥ 500 IU/L) with abdominal pain, then the pancreatic stent was removed 1 d after ERCP. In other cases, pancreatic stents with a flap were removed 2-3 d after ERCP, but pancreatic stents without a flap were not removed. JF260V, JF240, and TJF240 ERCP endoscopes (Olympus, Tokyo, Japan) were used. A Tandem XL (Boston Scientific Japan, Tokyo, Japan), MTW ERCP catheter taper (MTW Endoskopie, Wesel, Germany), or PR-233Q (Olympus) was used as the ERCP catheter. A CleverCut 3V (Boston Scientific Japan, Tokyo, Japan) was used for endoscopic sphincterotomy (EST). An RX Needle Knife (Boston Scientific Japan, Tokyo, Japan) was used to precut Vater's papilla. A Zimmon 5-Fr, 2-cm single pigtail stent without an inner flap (Cook Japan, Tokyo, Japan), a Zimmon 5-Fr, 4-cm single pigtail stent with an inner flap (Cook Japan, Tokyo, Japan), a Geenen 5-Fr, 3-cm stent with outer flaps and without an inner flap (Cook Japan, Tokyo, Japan), or a Geenen 5-Fr, 5-, 7-, or 9-cm stent with inner flaps and outer flaps was used as the pancreatic stent.

Examined parameters
-------------------

Patient characteristics (age, gender, pancreatic calcification, parapapillary diverticulum, and diameter of the MPD) and ERCP factors (EST, endoscopic papillary balloon dilation (EPBD), precut of Vater's papilla, procedure time, serum levels of p-AMY, PEP, and pancreatic stent migration within 1 wk) were compared between the head group and the body/tail group. The p-AMY value peaked within 1 wk of ERCP. The level of p-AMY was measured 3 h and 24 h after ERCP. If the level of serum amylase was more than three times the normal level 24 h after ERCP, with p-AMY accounting for the majority of the change in serum amylase, we measured p-AMY every day until the serum amylase level decreased to approximately two times the normal level or to a normal level. PEP was diagnosed by hyperamylasemia more than three times the normal level at more than 24 h after ERCP and abdominal pain\[[@B27]\]. In addition, we confirmed peripancreatic inflammation by contrast computed tomography (CT) imaging in all PEP patients. The severity of PEP was determined as proposed by Cotton et al\[[@B27]\] (mild: hospitalization prolonged for 2-3 d; moderate: 4-10 d; and severe: more than 10 d, or pseudocyst requiring intervention (percutaneous drainage or surgery), or hemorrhagic pancreatitis). Pancreatic stent migration was confirmed randomly by X-ray or CT.

Statistical analyses
--------------------

Kolmogorov-Smirnov tests and Shapiro-Wilk normality tests were used to test normality. Mann-Whitney *U* tests were used to compare continuous variables. Fisher's exact tests were used to compare nominal variables. Logistic regression was used to investigate post-ERCP hyperamylasemia factors. A *P* value \< 0.05 was considered to indicate a statistically significant difference. All statistical analyses were performed using the EZR platform (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). More precisely, EZR is a modified version of R commander that was designed to perform functions frequently used in biostatistics\[[@B28]\].

RESULTS
=======

Patient characteristics were not significantly different between the two groups (Table [1](#T1){ref-type="table"}). Regarding aspects of the ERCP procedures, the p-AMY levels after ERCP in the head group were significantly higher than those in the body/tail group \[138.5 (7.0-2086) IU/L *vs* 78.5 (5.0-1266.5), *P =* 0.03\] \[median (range)\] (Table [2](#T2){ref-type="table"}). Other factors were not different between the two groups, and PEP did not occur in the body/tail group. However, PEP occurred in 12 patients in the head group (mild 2; moderate 8; and severe 2).

###### 

Comparison of patient demographic and clinical characteristics *n* (%)

                                              **Head group (*n* = 131)**                  **Body/tail group (*n* = 16)**   ***P* value**
  ------------------------------------------- ------------------------------------------- -------------------------------- ---------------
  Age, median (range), yr                     71.0 (29-97)                                66.5 (26-81)                     0.052
  Male/female                                 69/62                                       11/5                             0.29
  Pancreatic calcification                    4 (3.1)[1](#T1FN1){ref-type="table-fn"}     1 (6.3)                          0.45
  Parapapillary diverticulum                  38 (29.5)[2](#T1FN2){ref-type="table-fn"}   5 (31.2)                         1.0
  Diameter of the MPD, median (range), mm     3.1 (0.7-22.0)                              3.7 (1.5-13.8)                   0.15
  Diagnosis                                                                                                                
  Left hepatic duct extension                 1                                                                            
  Biliary stricture                                                                                                        
  Benign                                      5                                                                            
  Malignant                                                                                                                
  Pancreatic cancer                           24                                          7                                
  Biliary tract cancer                        33                                          3                                
  Hepatocellular carcinoma                    3                                                                            
  Obstructive jaundice by metastatic cancer                                                                                
  Barrett's esophageal cancer                                                             1                                
  Colon cancer                                4                                                                            
  Gastric cancer                              2                                                                            
  Uterine cancer                              1                                                                            
  Bladder cancer                              1                                                                            
  Ovarian cancer                              1                                                                            
  Suppression of lymph node swelling          1                                                                            
  Central bile duct stone                     47                                          4                                
  Primary sclerosing cholangitis              1                                           1                                
  Gallbladder adenomyosis                     3                                                                            
  IPNB                                        1                                                                            
  Sphincter of Oddi dysfunction               1                                                                            
  Biliary cysts                               1                                                                            
  Lemmel syndrome                             1                                                                            

Data from four cases were not available;

Data from two cases were not available. MPD: Main pancreatic duct.

###### 

Comparison of endoscopic retrograde cholangiopancreatography procedures *n* (%)

                                           **Head group (*n* = 131)**                         **Body/tail group (*n* = 16)**                ***P* value**
  ---------------------------------------- -------------------------------------------------- --------------------------------------------- ---------------
  EST                                      98 (75.4)                                          15 (93.8)                                     0.12
  Precut of Vater's papilla                43 (33.1)                                          5 (31.3)                                      1
  EPBD                                     8 (6.2)                                            0 (0)                                         0.6
  Pancreatic stent migration within 1 wk   26 (19.8)                                          0 (0)                                         0.076
  Procedure time, median (range), min      60 (20-150)[1](#T2FN1){ref-type="table-fn"}        60 (40-120)[2](#T2FN2){ref-type="table-fn"}   0.31
  Type of stent                                                                                                                             
  Zimmon 5 Fr, 2 cm                        3                                                                                                
  Zimmon 5 Fr, 4 cm                        1                                                                                                
  Geenen 5 Fr, 3 cm                        59                                                                                               
  Geenen 5 Fr, 5 cm                        58                                                                                               
  Geenen 5 Fr, 7 cm                        11                                                 12                                            
  Geenen 5 Fr, 9 cm                                                                           4                                             
  p-AMY after ERCP, median (range), IU/L   138.5 (7.0-2086)[3](#T2FN3){ref-type="table-fn"}   78.5 (5.0-1266.5)                             0.03
  PEP                                      12 (9.2)                                           0 (0)                                         0.363
  Mild                                     2                                                                                                
  Moderate                                 8                                                                                                
  Severe                                   2                                                                                                

Data from three cases were not available;

Data from one case were not available;

Pancreatic amylase data from seven cases were not available, but the level of serum amylase was not elevated. EPBD: Endoscopic papillary balloon dilation; p-AMY: Pancreatic amylase isoenzyme; PEP: Pancreatitis.

Regarding the risk factors of post-ERCP hyperamylasemia (≥ p-AMY median, 131 IU/L), age ≥ 71 years, parapapillary diverticulum, stent insertion into the pancreatic head, and procedure time ≥ 60 min were identified as significant factors in the univariate analysis (factors with *P* \< 0.15 were selected for multivariate analysis) (Table [3](#T3){ref-type="table"}). Logistic regression with backward stepwise selection was performed using these four items, and the independent risk factors included procedure time ≥ 60 min \[odds ratio (OR) 2.65, 95%CI: 1.17-6.02, *P =* 0.02\] and stent insertion into the pancreatic head (OR 3.80, 95%CI: 1.12-12.9, *P =* 0.032) (Table [4](#T4){ref-type="table"}).

###### 

Risk factors of post-endoscopic retrograde cholangiopancreatography hyperamylasemia (≥ pancreatic amylase isoenzyme median, 131 IU/L) (univariate analysis) *n*

                                             **p-AMY \< 131 IU/L[1](#T3FN1){ref-type="table-fn"} (*n* = 70)**   **p-AMY ≥ 131 IU/L[1](#T3FN1){ref-type="table-fn"} (*n* = 70)**   ***P* value**
  ------------------------------------------ ------------------------------------------------------------------ ----------------------------------------------------------------- ---------------
  Age (≥ 71 yr)                              29                                                                 41                                                                0.063
  Gender (male/female)                       40/30                                                              35/35                                                             0.5
  Pancreatic calcification                   3                                                                  2                                                                 1
  Parapapillary diverticulum                 27                                                                 16                                                                0.043
  MPD ≥ 3.2 mm                               36                                                                 36                                                                1.0
  EST                                        52                                                                 55                                                                0.69
  EPBD                                       3                                                                  3                                                                 1.0
  Precut of Vater's papilla                  18                                                                 26                                                                0.20
  Stent inserted pancreatic head             58                                                                 66                                                                0.06
  Pancreatic stent migration within a week   11                                                                 12                                                                1.0
  Procedure time ≥ 60 min                    45                                                                 57                                                                0.048

Pancreatic amylase data were not available in seven cases, but the level of serum amylase was not elevated. MPD: Main pancreatic duct; EPBD: Endoscopic papillary balloon dilation.

###### 

Risk factors for post-endoscopic retrograde cholangiopancreatography hyperamylasemia (≥ pancreatic amylase isoenzyme median, 131 IU/L) (multivariate analysis by logistic regression with backward stepwise selection)

                                             **OR**   **95%CI**   ***P* value**
  ------------------------------------------ -------- ----------- ---------------
  Procedure time ≥ 60 min                    2.65     1.17-6.02   0.020
  Stent insertion into the pancreatic head   3.80     1.12-12.9   0.032

DISCUSSION
==========

In this study, we investigated how far a pancreatic stent should be inserted. We compared several factors between the head group and the body/tail group. P-AMY levels after ERCP were significantly higher in the head group than in the body/tail group. PEP did not occur in the body/tail group. Stent insertion into the pancreatic head was an independent risk factor for hyperamylasemia after ERCP.

Several reports are available regarding the diameter of pancreatic stents. Lawrence et al\[[@B29]\] reported that 3-Fr pancreatic stents passed spontaneously and did not induce changes in the pancreatic duct. Zolotarevsky et al\[[@B24]\] reported that placement of a 5-Fr pancreatic stent was easier, faster, and required fewer wires compared to a 3-Fr pancreatic stent. Pahk et al\[[@B25]\] reported that 4-Fr pancreatic stents migrated more frequently than 5-Fr pancreatic stents; therefore, the need for additional endoscopy to retrieve the pancreatic stent was reduced by using a 4-Fr pancreatic stent. However, PEP was no less common with the slimmer stents in these reports.

This report showed that pancreatic stent placement in the pancreatic body or tail could reduce the rates of post-ERCP hyperamylasemia and PEP. Difficulty with pancreatic duct drainage leads to proteinase activation, which exacerbates pancreatitis\[[@B30]\]. Pancreatic stent placement up to the pancreatic body or tail could allow greater pancreatic duct drainage than stent placement in the pancreatic head. Therefore, stent placement up to the pancreatic body or tail may reduce the risks of PEP and post-ERCP hyperamylasemia. In addition, no pancreatic stent migration was observed in the body/tail group. Therefore, the risk of pancreatic stent obstruction by contact with the duodenal wall was considered to be low.

This study has some limitations. First, this was a retrospective study with a small number of patients at a single institution. In addition, we generally insert stents into the pancreatic head, as described in past reports; we only recently began inserting pancreatic stents up to the body or tail of the pancreas. Therefore, the number of patients in the body/tail group was small. We hope to conduct larger prospective studies to verify the findings of this study. We performed a multivariate analysis, including post-ERCP serum p-AMY levels, and were able to identify the risk factors for post-ERCP hyperamylasemia. Second, many patients were excluded from this study. However, the amount of contrast media used in 102 patients to investigate the pancreatic duct by pancreatography was much higher than the target amount of this study. The risk of PEP in the 102 excluded patients was very different from that in the general population, as many of these excluded patients had chronic pancreatitis. In addition, many patients with pancreatic stricture underwent pancreatic stenting as treatment rather than for the prevention of PEP. Therefore, the patients included in the present study and the 102 patients excluded from the study could not be compared. Third, due to the retrospective nature of this study, ERCP procedures were not performed by specific endoscopists. In this study, ERCP was performed by specialists in pancreaticobiliary endoscopy who had experience in performing at least 2000 ERCP procedures or by trainees under the guidance of these specialists. Therefore, the quality of the ERCP procedure was considered to be consistent. Fourth, stents without an inner flap (Geenen 5 Fr, 3 cm and Zimmon 5 Fr, 2 cm) were used in only the head group. Consequently, the stent migration rate was higher in the head group than in the body/tail group. In past reports, however, incidence of spontaneous pancreatic stent migration did not subsequently result in increased incidence of PEP\[[@B25],[@B26],[@B31]\]. Therefore, using a stent without an inner flap was not considered disadvantageous in the head group.

In conclusion, stent insertion up to the pancreatic body or tail reduced the incidence of post-ERCP hyperamylasemia and may reduce the incidence of PEP.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Pancreatic stents are reported to be useful for preventing pancreatitis (PEP).

Research motivation
-------------------

We wanted to determine the appropriate length of a pancreatic stent for preventing PEP.

Research objectives
-------------------

To investigate whether a stent should be inserted into the pancreatic head, body, or tail to prevent PEP.

Research methods
----------------

Patient characteristics and endoscopic retrograde cholangiopancreatography (ERCP) factors were compared between 131 patients with a stent inserted into the pancreatic head (head group) and 16 patients with a stent inserted up to the pancreatic body or tail (body/tail group).

Research results
----------------

Pancreatic amylase isoenzyme (p-AMY) levels after ERCP were significantly higher in the head group than in the body/tail group. PEP did not occur in the body/tail group. Stent insertion into the pancreatic head was an independent risk factor for hyperamylasemia after ERCP.

Research conclusions
--------------------

Stent insertion up to the pancreatic body or tail reduced the incidence of post-ERCP hyperamylasemia and may reduce the incidence of PEP.

Research perspectives
---------------------

Prophylactic stent insertion up to the pancreatic body or tail may be the main method for preventing PEP. We hope that a future prospective, multicenter study will confirm the conclusion of this study.
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